Literature DB >> 3007307

Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.

M M Homeida, T K Daneshmend, E M Ali, A G Yousif-Elkadaru, B M Arbab.   

Abstract

The hypothesis that an increased rate of oxidative metabolism may be an initiator or promoter of hepatocellular carcinoma was tested in vivo. Elimination of antipyrine (phenazone) was used as an index of the activity of microsomal mixed function oxidative enzymes. Plasma antipyrine kinetics were examined in 10 patients with hepatocellular carcinoma and in 10 normal Sudanese adults. The half life, volume of distribution and clearance of antipyrine in patients were 18.8 +/- 7.9 hours (mean +/- SD), 33.8 +/- 7.7 litres and 23.7 +/- 10.1 ml/min, respectively; and in normal adults were 20.3 +/- 8.8 hours, 40.1 +/- 10.4 litres and 25.7 +/- 12.0 ml/min, respectively. These differences were not significant. Antipyrine plasma clearance when corrected for weight was similar in the two groups. This study suggests that in a population at risk for hepatocellular carcinoma, the overall activity of mixed function oxidative enzymes is not an important determinant in selectively increasing this risk.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007307      PMCID: PMC1433382          DOI: 10.1136/gut.27.4.382

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Impairment of drug metabolism in patients with liver cancer.

Authors:  E A Sotaniemi; R O Pelkonen; R E Mokka; R Huttunen; E Viljakainen
Journal:  Eur J Clin Invest       Date:  1977-08       Impact factor: 4.686

2.  Summary of United States--Japan Cooperative Seminar on Human Hepatocarcinogenesis, January 20-22, 1983, in Honolulu, Hawaii.

Authors:  H Popper; W Mori
Journal:  J Natl Cancer Inst       Date:  1983-11       Impact factor: 13.506

3.  Carcinogens, drugs, and cytochromes P-450.

Authors:  H V Gelboin
Journal:  N Engl J Med       Date:  1983-07-14       Impact factor: 91.245

4.  Further studies on the increase in drug-metabolizing capacity adjacent to intrahepatic Morris hepatomas.

Authors:  L G Sultatos; D K Liu; E S Vesell
Journal:  Biochem Pharmacol       Date:  1981-05-01       Impact factor: 5.858

5.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

6.  Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.

Authors:  D Vuitton; J P Miguet; G Camelot; C Delafin; C Joanne; P Bechtel; M Gillet; P Carayon
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

7.  Enhanced drug-metabolizing capacity within liver adjacent to human and rat liver tumors.

Authors:  L G Sultatos; E S Vesell
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Enhancement of diethylnitrosamine hepatocarcinogenesis in rats by exposure to polychlorinated biphenyls or phenobarbital.

Authors:  M Nishizumi
Journal:  Cancer Lett       Date:  1976-09       Impact factor: 8.679

9.  Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.

Authors:  M Homeida; S Y Salih; R A Branch
Journal:  Gut       Date:  1978-09       Impact factor: 23.059

10.  Hepatocellular carcinoma in the non-cirrhotic liver: a comparison with that complicating cirrhosis.

Authors:  W M Melia; M L Wilkinson; B C Portmann; P J Johnson; R Williams
Journal:  Q J Med       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.